Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    Proellex
Show Display Options
Rank Status Study
1 Completed
Has Results
Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
Condition: Impaired Liver Function
Intervention: Drug: Proellex
2 Completed Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females
Conditions: ABSORPTION;   METABOLISM;   EXCRETION
Intervention: Drug: Proellex
3 Terminated
Has Results
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: Proellex 25 mg;   Drug: Proellex 50 mg
4 Terminated Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
Condition: Endometriosis
Intervention: Drug: Proellex®
5 Terminated
Has Results
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
Condition: Renal Impairment
Intervention: Drug: 50 mg Proellex
6 Completed Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: 12.5 mg Proellex;   Drug: 25 mg Proellex;   Drug: Placebo
7 Terminated
Has Results
Study to Evaluate Menses Induction in Women Administered Proellex
Condition: Amenorrhea
Interventions: Drug: Placebo;   Drug: Proellex
8 Completed Proellex® Pharmacokinetic Bridging Study II
Condition: Healthy
Intervention: Drug: Proellex 25 mg
9 Completed
Has Results
A Safety and Pharmacokinetic Study of Proellex®
Condition: Healthy
Intervention: Drug: Proellex
10 Terminated
Has Results
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Condition: Uterine Fibroids
Intervention: Drug: 25 mg Proellex
11 Withdrawn Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms
Condition: Uterine Fibroids
Intervention: Drug: Proellex
12 Terminated
Has Results
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: Proellex 25 mg;   Drug: Proellex 50 mg;   Drug: Lupron Depot
13 Terminated
Has Results
Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: Proellex;   Drug: Placebo
14 Terminated
Has Results
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: Proellex;   Other: placebo
15 Completed Proellex Pharmacokinetics Bridging Study
Condition: Healthy
Interventions: Drug: 25 mg Proellex;   Drug: 50 mg Proellex
16 Completed Comparison of Two Formulations of Proellex for Vaginal Administration
Condition: Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Interventions: Drug: Proellex Formulation A;   Drug: Proellex Formulation B
17 Completed Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Condition: Uterine Fibroids
Interventions: Drug: Proellex 12 mg;   Drug: Proellex 24 mg
18 Terminated
Has Results
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Conditions: Uterine Fibroids;   Anemia
Interventions: Drug: Proellex 25 mg;   Drug: Proellex 50 mg;   Drug: Placebo
19 Completed
Has Results
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Condition: Uterine Fibroids
Intervention: Drug: Proellex
20 Active, not recruiting A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Condition: Uterine Fibroids
Interventions: Drug: Telapristone Acetate;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.